Gabapentin Capsule
Product Images NDC 71335-2521

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2521). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Equation)

An equation illustrating the formula for calculating creatinine clearance (CLCr), showing variables including age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor of 0.85 for female patients.*

FDA Label Image

Fig 1 (Fig 1)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' comparing mean pain scores over 8 weeks between placebo and gabapentin at 3600 mg/day. The graph shows a decrease in pain score for gabapentin during the fixed dose period, whereas the placebo group maintains a higher, relatively constant pain score.*

FDA Label Image

Fig 2 (Fig 2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores on the y-axis and weeks on the x-axis. It compares placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day over a baseline, 4-week dose titration period, and a 4-week fixed dose period. Gabapentin groups show decreasing pain scores over time compared to placebo.*

FDA Label Image

Fig 3 (Fig 3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. Study 1 compares placebo (12%) and gabapentin 3600 mg (29%). Study 2 compares placebo (14%), gabapentin 1800 mg (32%), and gabapentin 2400 mg (34%). Asterisks indicate statistical significance levels (p <0.01 and p <0.001).*

FDA Label Image

Fig 4 (Fig 4)

A graph depicting the responder rate in patients receiving gabapentin as a difference from placebo, shown by daily dose in mg on the x-axis and percentage difference on the y-axis. The chart compares data from three studies (a, b, and c) involving patients aged 12 years and older with partial seizures. Data points for studies a, b, and c are represented with different markers across doses of approximately 600, 900, 1200, and 1800 mg.*

FDA Label Image

Structure (Struct)

Chemical structure of gabapentin showing a cyclohexane ring attached to an amino and a carboxymethyl group.*

FDA Label Image

Label (Lbl713352521)

Label for Gabapentin Capsules USP 300 mg, containing 30 capsules. The label includes the NDC 71335-2521, directions to store at 20° to 25°C with permitted excursions, and a warning to keep out of reach of children. It shows the repackager Bryant Ranch Prepack and manufacturer Ascent Pharmaceuticals, with QR codes for package insert and product information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.